Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | OGG1 | O15527 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1355978 | 0.81 | SMN1; SMN2 (0.34) | OGG1SMN1; SMN2HSD17B10HCAR2 | |
| SCHEMBL1357675 | 0.80 | HTR6 (0.39) | HDAC1OGG1SMN1; SMN2HSD17B10PTGDR2 | |
| Fumaric Acid SCHEMBL1357277 | 0.79 | HDAC1 (0.38) | HDAC1MMP13OGG1SMN1; SMN2HSD17B10 | |
| SCHEMBL3696946 | 0.77 | FFAR1 (0.33) | HCAR2 | |
| SCHEMBL3703507 | 0.76 | POLB (0.33) | SMN1; SMN2HCAR2 | |
| SCHEMBL3701641 | 0.75 | CTSA (0.31) | — | |
| SCHEMBL3696441 | 0.74 | HCAR2 (0.34) | HDAC1SMN1; SMN2HCAR2 | |
| SCHEMBL9611273 | 0.73 | ADRB2 (0.41) | HDAC1MMP13OGG1SMN1; SMN2HSD17B10 | |
| SCHEMBL3691869 | 0.72 | FFAR1 (0.32) | HCAR2 | |
| SCHEMBL4120943 | 0.70 | HCAR2 (0.31) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2005957-B1 | ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-20110288040-A1 | ARYL- OR HETEROARYL-SULFONYL COMPOUNDS AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-24 | — | — | US | disclosed |
| US-7994205-B2 | Aryl-or heteroaryl-sulfonyl compounds as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20090118335-A1 | Acid Secretion Inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-2005957-A1 | ACID SECRETION INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118335-A1 | Acid Secretion Inhibitor | ATP6AP1, HRH2, ATP6V1G1 | HDAC1 577/4885MMP13 1553/4885OGG1 4143/4885 |
| US-20110288040-A1 | ARYL- OR HETEROARYL-SULFONYL COMPOUNDS AS ACID SECRETION INHIBITORS | GHSR, GIPR, HRH2 | HDAC1 665/4885MMP13 1986/4885OGG1 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.